Adagio Medical Holdings Inc
perceptivelife.comAdagio Medical Holdings Inc (NASDAQ: ADGM) is a medical device company focused on developing catheter-based cardiac ablation systems for the treatment of cardiac arrhythmias. The company has not yet generated commercial revenue from its primary product pipeline and is operating as a pre-revenue, clinical-stage device company as of its 10-K filed March 27, 2026. Adagio Medical became a public company through a business combination with ARYA Sciences Acquisition Corp IV, closing in 2024, with ListCo renamed Adagio Medical Holdings, Inc. upon closing. The company reported net cash used in operating activities of $19.0 million for the year ended December 31, 2025 (Successor period) and $13.5 million for the Successor period July 31 to December 31, 2024, reflecting a development-stage cost structure funded primarily through equity and convertible note financing. The iCLAS Cryoablation System was a former product candidate that the company is no longer pursuing following a serious adverse event in 2021. Product commercialization depends on FDA clearance or approval and third-party payor reimbursement.
Products & Services
The company is developing catheter-based cardiac ablation products. The iCLAS Cryoablation System (iCLAS Cryoablation Catheter and associated console) was a prior product candidate that held CE mark for commercial sale in the EU but is no longer being pursued following a patient death during the U.S. pivotal IDE clinical study in 2021. Current product pipeline details are not specified in the provided filing excerpts.
Revenue Model
The company has not disclosed commercial product revenue in the filing excerpts provided. Operations are financed through equity issuances and convertible notes, including $29.5 million in Bridge Financing Notes and a $15.9 million cash investment from the Perceptive PIPE Investor at the time of the 2024 business combination.
Customers & Markets
Target end markets are hospitals and electrophysiology physicians treating patients with cardiac arrhythmias. Commercialization depends on coverage and reimbursement from third-party payors, including Medicare, Medicaid, managed care organizations, and private health insurers in the United States, as well as country-by-country reimbursement approvals in international markets.
Geographic Exposure
The company operates in the United States and has had CE-marked product activity in the European Union. International operations are subject to GDPR (EU and UK), Brazil's LGPD, and China's PIPL data privacy frameworks, indicating a multi-jurisdiction operational footprint, though specific revenue by geography is not disclosed in the provided excerpts.
Source: SEC 10-K, filed 2026-03-27
Financial Snapshot
Loading...
